Gene injection aims to restore hearing in deaf children
NCT ID NCT07288580
Summary
This early-stage trial is testing an experimental gene therapy called EHT102 in children aged 1-17 who have profound hearing loss caused by specific mutations in the OTOF gene. Up to 30 participants will receive a single injection into one ear to see if it is safe and if it can improve their hearing sensitivity. The study will carefully monitor for side effects and measure changes in hearing ability over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT OF CONGENITAL HEARING LOSS SECONDARY TO BIALLELIC MUTATIONS OF THE OTOFERLIN GENE (OTOF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.